Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Blockbuster GLP-1 medications like Ozempic and Mounjaro might sharpen your figure, but they could also cloud your vision in ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Other GLP-1 agonists, including Zepbound, can cause hair loss. Read on to learn more about hair loss and GLP-1 agonists as well as more common side effects to expect with Mounjaro. dulaglutide ...

Its lineup features several blockbusters, including its popular diabetes and weight loss medicines, Mounjaro and Zepbound. It's true that these drugs' sales are not increasing quite as fast as ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

Zepbound, another weight-loss drug, was taken off the compounding list in December after manufacturer Eli Lilly increased production. The same is expected to happen soon for Wegovy, which is made ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

In Q4 2024, the company saw a 45% increase in revenue, reaching $13.53 billion, driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled ...

and tirzepatide (Mounjaro/Zepbound). Seven of the nine patients developed a condition known as nonarteritic anterior ischemic optic neuropathy (NAION). This occurs when blood vessels fail to ...